search
Back to results

Efficacy of a Novel CCH Protocol for PD Among Prior Non-responders

Primary Purpose

Peyronie's Disease

Status
Recruiting
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
CCH administration
Control - Crossover to CCH
RestoreX
Sponsored by
Charitable Union for the Research and Education of Peyronie's Disease
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Peyronie's Disease

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)MaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Men with Peyronie's Disease
  • >18 years old
  • Curvature ≥30 degrees
  • Previously completed 6-8 CCH injections
  • Prior minimal (<20% and/or <10 degrees) responsiveness to CCH administration
  • Prior CCH injections must have been performed without use of a Restorex traction device and used the IMPRESS protocol
  • Ability to achieve an erection satisfactory for intercourse with or without PDE5 inhibitors
  • The patient exhibits a palpable plaque consistent with Peyronie's Disease

Exclusion Criteria:

  • Prior surgical treatment on the penis (other than circumcision)
  • Any contraindications to CCH - as determined by the PI
  • Inability to complete 8 additional CCH injections
  • Severe plaque calcification (i.e. >1 cm shadowing)

Sites / Locations

  • The Male Fertility and Peyronie's ClinicRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

Control - Crossover to CCH

Collagenase Clostridium Histolyticum

Arm Description

Men in this cohort would undergo baseline assessments followed by no treatment for 6 months and then repeat assessments. Men would then cross-over to CCH treatment and undergo up to 8 injections (or until curvature is <15 degrees). Final assessments would then be performed 6 weeks following the final injection.

Men in this cohort would undergo baseline assessments followed by up to 8 injections of CCH (or until curvature is <15 degrees). Men would then undergo assessments 6 weeks later, followed by a 6-month no treatment phase and then final assessments.

Outcomes

Primary Outcome Measures

Penile Curvature
Compare the change in degree of penile curvature from baseline (using a goniometer) between control and treatment groups at 6 months
Peyronie's Disease Questionnaire Outcomes
Compare Peyronie's Disease Questionnaire outcomes between control and treatment groups at 6 months using the Peyronie's Disease Questionnaire (15 items; subdomains - psychological and physical (Q1-6, 0-24), penile pain (Q7-9; 0-30), symptom bother (Q10-15; 0-16); 12 and 14 (Y/N q's); lower is better.

Secondary Outcome Measures

International Index of Erectile Function Outcomes
Compare International Index of Erectile Function Outcomes between control and treatment groups at 6 months
Penile Curvature Compared to Baseline
Compare penile curvature changes (degrees) in control men at baseline and 12 months (i.e. prior to and following cross-over to CCH) - using goniometer
Penile Length Compared to Baseline
Compare penile length changes in control men at baseline and 12 months (i.e. prior to and following cross-over to CCH)
Compare Peyronie's Disease Questionnaire to Baseline
Compare PDQ changes in control men at baseline and 12 months (i.e. prior to and following cross-over to CCH) using the Peyronie's Disease Questionnaire (15 items; subdomains - psychological and physical (Q1-6, 0-24), penile pain (Q7-9; 0-30), symptom bother (Q10-15; 0-16); 12 and 14 (Y/N q's); lower is better.
Compare International Index of Erectile Function to baseline
Compare International Index of Erectile Function changes in control men at baseline and 12 months (i.e. prior to and following cross-over to CCH)
Penile Length Between Groups
Compare penile length changes between control and treatment groups at 6 months
Adverse events - 6 months - pain, sensation, swelling
Report adverse events at the 6-month time point
Adverse events - 12 months - pain, sensation, swelling
Report adverse events at the 12-month time point
Change in penile curvature durability
Report changes in penile curvature degree between the 6 and 12-month assessments for CCH men by goniometer.

Full Information

First Posted
October 11, 2021
Last Updated
September 11, 2023
Sponsor
Charitable Union for the Research and Education of Peyronie's Disease
search

1. Study Identification

Unique Protocol Identification Number
NCT05108558
Brief Title
Efficacy of a Novel CCH Protocol for PD Among Prior Non-responders
Official Title
Efficacy of a Novel Collagenase Clostridium Histolyticum Protocol for Peyronie's Disease Among Prior Non-responders: A Randomized, Controlled, Single-Blinded Study
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Recruiting
Study Start Date
September 20, 2021 (Actual)
Primary Completion Date
September 20, 2023 (Anticipated)
Study Completion Date
September 20, 2028 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Charitable Union for the Research and Education of Peyronie's Disease

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
Yes

5. Study Description

Brief Summary
Compare key clinical outcomes between controls and men treated with a novel CCH administration protocol among men previously unresponsive to CCH administration.
Detailed Description
Beginning approximately 3 years ago, the investigators' team sought to achieve further improvements with CCH through the addition of more aggressive modeling therapies. Results from a comparison of CCH alone vs CCH and traction with RestoreX demonstrated a mean 33.8 degree (49%) curvature improvement with combined therapy compared to 19-20 degrees (30-31%) with CCH alone or CCH and other traction devices). These results currently represent the greatest improvements with CCH in published literature and further build upon phase IIb results which demonstrated that mechanical traction (via manual modeling in the phase IIb trial) represents a critical factor in achieving improvements with CCH. The investigators' team additionally published a survey of men who had experienced suspected penile fractures with CCH and demonstrated greater curvature improvements without any loss / worsening of erectile function. This critical study highlighted that conservative management of suspected fractures should not only be considered a standard of care in managing suspected fractures, but also that these men achieved better final outcomes (again highlighting the importance of the combination of mechanical curvature correction in addition to CCH management). Based on the above findings, the investigators' team began performing a more aggressive manual modeling protocol. This novel protocol included several notable innovations: dilution of the 0.9 mg of CCH in 0.7 ml of diluent, injection to the erect penis to assure accurate injection, repeat curvature assessments with each series (due to changing of the point of maximal curvature), incorporation of RestoreX traction therapy post injection, and 'aggressive' manual modeling (equivalent of 10-15 lbs of force) to achieve curvature correction. Preliminary (unpublished - abstract submitted to SMSNA 2021) results from these men demonstrated a median ~60% curvature improvement. Importantly, several of the patients had previously undergone 8 CCH injections with outside providers and were able to similarly achieve a median 60% improvement with the investigators' injection / modeling protocol. These preliminary findings have several important ramifications for the treatment of PD: Men who have previously not achieved adequate curvature correction with 4 series of CCH injections may benefit from additional injections using a more aggressive traction protocol. A more aggressive traction protocol would benefit patients to achieve greater outcomes than with previously reported protocols. 1.2 Investigational Treatments The current study would randomize men 1:3 into one of two treatment cohorts: 1. Observation followed by CCH or 2. CCH followed by observation. This study design offers the benefits of a randomized, controlled trial (highest level of evidence). RCTs are particularly important in PD, where the disease changes over time in a percentage of men as a function of its natural history. This would also allow blinding of measurements using photographs (single-blinded assessments), which provides further study rigor. No treatment (control) followed by CCH. Men in this cohort would undergo baseline assessments followed by no treatment for 6 months and then repeat assessments. Men would then cross-over to CCH treatment and undergo up to 8 injections (or until curvature is <15 degrees). Interval assessments would be performed with the 1st injection of each series, and final assessments would then be performed 6 weeks following the final injection. CCH followed by no treatment. Men in this cohort would undergo baseline assessments followed by up to 8 injections of CCH (or until curvature is <15 degrees). Interval assessments would be performed with the 1st injection of each series and 6 weeks following completion of treatment. Men then would not undergo any additional treatments for 6 months, after which final assessments would then performed.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Peyronie's Disease

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Model Description
Patients meeting criteria who have consented will be randomized to either control or CCH x 6 months, followed by a cross-over phase where controls will receive CCH. See Figure 1 for full study schema. Control. Men in this cohort would undergo baseline assessments followed by no treatment for 6 months and then repeat assessments. Men would then cross-over to the CCH treatment phase and undergo up to 8 injections (or until curvature is <15 degrees, whichever comes first). Final assessments would then be performed 6 weeks following the final injection. CCH followed by observation. Men in this cohort would undergo baseline assessments followed by up to 8 injections of CCH (or until curvature is <15 degrees). Assessments would then be performed 6 weeks after completion of treatment. Men then would not undergo any additional treatments for 6 months, after which they would have final assessments performed.
Masking
Care ProviderOutcomes Assessor
Masking Description
Photography will be obtained where possible, with outcomes assessed based on the photographs. The care provider obtaining measurements will also be blinded as to baseline outcomes and results with follow-up assessments.
Allocation
Randomized
Enrollment
40 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Control - Crossover to CCH
Arm Type
Active Comparator
Arm Description
Men in this cohort would undergo baseline assessments followed by no treatment for 6 months and then repeat assessments. Men would then cross-over to CCH treatment and undergo up to 8 injections (or until curvature is <15 degrees). Final assessments would then be performed 6 weeks following the final injection.
Arm Title
Collagenase Clostridium Histolyticum
Arm Type
Experimental
Arm Description
Men in this cohort would undergo baseline assessments followed by up to 8 injections of CCH (or until curvature is <15 degrees). Men would then undergo assessments 6 weeks later, followed by a 6-month no treatment phase and then final assessments.
Intervention Type
Drug
Intervention Name(s)
CCH administration
Other Intervention Name(s)
Collagenase Clostridium Histolyticum
Intervention Description
Patients will be randomized 3:1 into the CCH administration arm. After undergoing baseline assessments, this arm will receive up to 8 CCH injections, followed by final assessments 6 weeks later.
Intervention Type
Drug
Intervention Name(s)
Control - Crossover to CCH
Other Intervention Name(s)
Collagenase Clostridium Histolyticum
Intervention Description
Patients will be randomized 1:3 into the control arm. After undergoing baseline assessments, control men will not undergo treatments for 6 months. They will then have repeat assessments and receive up to 8 CCH injections. They will then have final assessments performed 6 weeks after treatment.
Intervention Type
Device
Intervention Name(s)
RestoreX
Intervention Description
Both treatment arms will incorporate the use of RestoreX for 30-60 minutes daily during CCH administration and continued until 6 weeks after final injection administration.
Primary Outcome Measure Information:
Title
Penile Curvature
Description
Compare the change in degree of penile curvature from baseline (using a goniometer) between control and treatment groups at 6 months
Time Frame
6 months
Title
Peyronie's Disease Questionnaire Outcomes
Description
Compare Peyronie's Disease Questionnaire outcomes between control and treatment groups at 6 months using the Peyronie's Disease Questionnaire (15 items; subdomains - psychological and physical (Q1-6, 0-24), penile pain (Q7-9; 0-30), symptom bother (Q10-15; 0-16); 12 and 14 (Y/N q's); lower is better.
Time Frame
6 months
Secondary Outcome Measure Information:
Title
International Index of Erectile Function Outcomes
Description
Compare International Index of Erectile Function Outcomes between control and treatment groups at 6 months
Time Frame
6 months
Title
Penile Curvature Compared to Baseline
Description
Compare penile curvature changes (degrees) in control men at baseline and 12 months (i.e. prior to and following cross-over to CCH) - using goniometer
Time Frame
12 months
Title
Penile Length Compared to Baseline
Description
Compare penile length changes in control men at baseline and 12 months (i.e. prior to and following cross-over to CCH)
Time Frame
12 months
Title
Compare Peyronie's Disease Questionnaire to Baseline
Description
Compare PDQ changes in control men at baseline and 12 months (i.e. prior to and following cross-over to CCH) using the Peyronie's Disease Questionnaire (15 items; subdomains - psychological and physical (Q1-6, 0-24), penile pain (Q7-9; 0-30), symptom bother (Q10-15; 0-16); 12 and 14 (Y/N q's); lower is better.
Time Frame
12 months
Title
Compare International Index of Erectile Function to baseline
Description
Compare International Index of Erectile Function changes in control men at baseline and 12 months (i.e. prior to and following cross-over to CCH)
Time Frame
12 months
Title
Penile Length Between Groups
Description
Compare penile length changes between control and treatment groups at 6 months
Time Frame
6 months
Title
Adverse events - 6 months - pain, sensation, swelling
Description
Report adverse events at the 6-month time point
Time Frame
6 months
Title
Adverse events - 12 months - pain, sensation, swelling
Description
Report adverse events at the 12-month time point
Time Frame
12 months
Title
Change in penile curvature durability
Description
Report changes in penile curvature degree between the 6 and 12-month assessments for CCH men by goniometer.
Time Frame
6 months

10. Eligibility

Sex
Male
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Men with Peyronie's Disease >18 years old Curvature ≥30 degrees Previously completed 6-8 CCH injections Prior minimal (<20% and/or <10 degrees) responsiveness to CCH administration Prior CCH injections must have been performed without use of a Restorex traction device and used the IMPRESS protocol Ability to achieve an erection satisfactory for intercourse with or without PDE5 inhibitors The patient exhibits a palpable plaque consistent with Peyronie's Disease Exclusion Criteria: Prior surgical treatment on the penis (other than circumcision) Any contraindications to CCH - as determined by the PI Inability to complete 8 additional CCH injections Severe plaque calcification (i.e. >1 cm shadowing)
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Landon Trost, MD
Phone
801-655-0015
Email
email@mfp.clinic
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Landon Trost, MD
Organizational Affiliation
CURE PD
Official's Role
Principal Investigator
Facility Information:
Facility Name
The Male Fertility and Peyronie's Clinic
City
Orem
State/Province
Utah
ZIP/Postal Code
84057
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Landon Trost, MD
Phone
888-655-0015
Email
trost.landon@mfp.clinic
First Name & Middle Initial & Last Name & Degree
Benjamin D. Green, Economics/MA
First Name & Middle Initial & Last Name & Degree
Holli Burgon

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Efficacy of a Novel CCH Protocol for PD Among Prior Non-responders

We'll reach out to this number within 24 hrs